argenx announces full exercise of underwritersa?? option to purchase additional ADSs

Regulated information a?? Inside information
November 8, 2019, 7:00 AM CET Breda, the Netherlands / Ghent, BelgiumA a?? argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today that the underwriters of its previously announced global offering of ordinary shares (including in the form of American Depositary Shares (ADSs)) have exercised their option to purchase 600,000 additional ADSs in full on the same terms and conditions as the global offering. This option exercise brings the anticipated total gross proceeds from the global offering to approximately $557 million (approximately a?¬502 million) from the sale of an aggregate of 4,600,000 ordinary shares (including in the form of ADSs).Morgan Stanley, Cowen, BofA Securities and Evercore acted as joint bookrunning managers for the offering. Kempen acted as lead manager for the offering and Wolfe Capital Markets and Advisory acted as co-manager.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Январь 2022    »